Attention should be paid to possible drowsiness, headache, indigestion, and hematological changes during the use of Japanese chloroaniline carbamate tablets.

1、 Drug name

1. Product Name: Chloroaniline Aminoformate Ingot

2. Common name: Chloroaniline Aminoformate

2、 Indications

Painful spasms associated with motor system diseases:

Lumbar and back pain, deformity of the spine, disc herniation, spinal separation/spondylolisthesis, spinal osteoporosis, neck, shoulder, and wrist syndrome.

3、 Specifications and characteristics

1. Specification: 250mg per tablet.

2. Dosage form: White vegetarian tablets.

3. 250mg specification: diameter 9.0mm, thickness 5.5mm, weight approximately 360mg, identification code "SW175".

4、 Main components

1. Active ingredient: Chlorophenesin Carbamate.

2. Additives: carboxymethyl cellulose calcium, light anhydrous silicic acid, crystalline cellulose, magnesium stearate, hydroxypropyl cellulose.

5、 Usage and dosage

1. 250mg specification: The standard dosage for adults is 1 tablet per time (250mg), taken orally 3 times a day. It can be adjusted according to age and symptoms.

2. Administration method: PTP packaged drugs should be taken out of the aluminum foil before administration, and direct ingestion of PTP sheets is strictly prohibited.

6、 Dose adjustment

1. Elderly people: It is necessary to reduce usage and pay attention to observation.

2. Liver function impairment: contraindicated for patients with liver dysfunction; Patients with a history of liver disease should be evaluated with caution.

3. Renal function impairment: According to foreign pharmacopoeias, it is recommended to use with caution.

4. Children: Clinical trials for children have not yet been conducted, and safety has not been established.

7、 Medication precautions (before and after meals, missed doses, vomiting, etc.)

1. Medication timing: Not clearly defined before or after meals.

2. Missed ingestion/vomiting: No specific treatment plan provided.

3. Precautions for operation: May cause drowsiness, decreased attention and reflex motor ability. It is prohibited to drive a car or engage in dangerous mechanical operations during medication.

4. PTP ingestion warning: It must be taken after removing PTP. Ingestion of sharp PTP tablets can puncture the esophageal mucosa, leading to serious complications such as perforation and mediastinitis.

5. Long term medication: Cases of medication administered for more than 8 weeks are limited. It is recommended to undergo regular blood, urine routine, and liver function tests for long-term medication.

8、 Medication for special populations

1. Pregnant women: Use only when the benefits of treatment outweigh the risks.

2. Breastfeeding women: It is necessary to consider both the necessity of treatment and the benefits of breastfeeding before deciding whether to continue or discontinue breastfeeding.

3. Children: Not recommended for use as clinical trials have not been conducted.

4. Elderly people: Physiological functions usually decline, it is recommended to reduce dosage and closely observe.

5. Patients with liver dysfunction: Absolute contraindication.

6. Patients with renal dysfunction: Use with caution.

9、 Adverse reactions

1. Major adverse reactions (frequency unknown):

Shock.

Toxic epidermal necrolysis (TEN).

2. Other adverse reactions (by frequency):

0.1-1% below: dizziness/shaking sensation, drowsiness, abdominal pain, indigestion, nausea, gastrointestinal disorders, rash.

Less than 0.1%: Headache/heaviness, fatigue, lethargy, diarrhea, constipation, dry mouth, glossitis, nausea, leukopenia, thrombocytopenia, swelling/swelling, itching, stomatitis, fever.

Unknown frequency: stomach discomfort, heartburn, loss of appetite, rash/medication rash.

3. Note: Abdominal pain includes stomach pain and discomfort; Digestive disorders include bloating, satiety, stomach heaviness, heartburn, and loss of appetite; The rash includes drug rash.

10、 Contraindications

1. Individuals with a history of allergies to this drug or similar compounds (such as metoclopramide).

2. Patients with liver dysfunction.

11、 Drug interactions

1. Combined medications: phenothiazine (chlorpromazine hydrochloride, etc.), central nervous system inhibitors (barbiturates, etc.), monoamine oxidase inhibitors, alcohol.

2. Clinical strategy: There may be a mutually reinforcing effect, and attention should be paid to adjusting the dosage.

3. Mechanism/risk factors: unknown.

12、 Storage method

Special temperature control conditions are not clearly indicated. Refer to general drugs stored at room temperature indoors to avoid contact with children.

13、 Manufacturer

Manufacturing and sales party: Sawai Pharmaceutical Co., Ltd.

Chlorphenesin Carbamate Tabletsinformation